Catalyst Wire Dossier Catalyst Wire Dossier

MK-4482 (Molnupiravir)

molnupiravir · Merck Sharp & Dohme LLC
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for MK-4482 (Molnupiravir), covering 2026-04-16 to 2026-04-16. Get the full timeline:

Most recent: Clinical Trial Update: A Clinical Study of MK-4482 in Chinese Healthy Male Participants (MK-4482-009) [Phase 1]

See pricing